Guardant Health has announced a distribution and marketing partnership with Oncotest-Teva. The partnership will make Guardant360®, Guardant Health’s groundbreaking, non-invasive genomic sequencing test for patients with advanced cancer, widely available to oncologists and patients in Israel. Guardant360 is the first commercially available comprehensive liquid biopsy.
It detects and analyzes DNA fragments from solid tumors that circulate in the blood of patients with advanced cancers.
Used in the United States by leading oncologist at top cancer centers, the test requires just a simple blood draw to detect all four major classes of somatic genomic alterations that cause solid tumors to grow and spread, and can help doctors select an appropriate targeted therapy. Oncotest-Teva will market Guardant360 and handle local sample logistics and patient reimbursement in Israel. Guardant Health will perform all testing at its CLIA-certified, CAP-accredited facilities in Redwood City, Calif.
“We’re excited to have Oncotest-Teva as a partner, and we look forward to seeing our test and technology help more patients,” said Helmy Eltoukhy, Guardant Health’s co-founder and CEO. “Patients fighting advanced cancer should not have to subject themselves to potentially risky biopsy procedures to get the best information about their cancer.” “Again and again we are impressed by the sensitivity and high accuracy of this technology to quickly and easily trap rare mutations in a patient’s blood,” said Nir Peled, MD PhD, Head of the Thoracic Cancer Unit at Davidoff Cancer Center, Rabin Medical Center, Israel.
“There is no question that this technology transforms oncology practice today. It should be noted that this test is currently not included in the Israeli healthcare basket.” “This is one of the biggest breakthroughs in the field of cancer genomics,” said Prof. Tamar Peretz, MD PhD, Head of the Sharett Institute of Oncology, Hadassah Medical Center, Jerusalem. “It allows us to pinpoint mutations in cancer without the need for biopsy. Now we can tackle the biggest obstacle in cancer treatment: progression and sustainability. Monitoring of treatment and early detection of acquired resistance will allow us to handle the complete range of cloning heterogeneity of the disease more accurately, quickly, and without a biopsy.”
“For nearly two decades Oncotest-Teva has been the pioneer and leader of personalized Oncology in Israel, actively engaged in bringing the most reliable innovative technologies to patients and physicians,” said Dr. Lior Soussan-Gutman, founder and managing director of Oncotest-Teva, Tel Aviv. “We are excited to provide Guardant360 in Israel, with its breakthrough liquid-biopsy sequencing technology that changes the treatment paradigm for cancer patients. We can now offer patients analysis of their tumor DNA quickly, and confront temporal and spatial limitations of tissue-based biopsies. We are proud to continue to lead personalized medicine in Israel.”
